Dainippon Sumitomo Pharma Co., Ltd.

Sumitomo Pharmaceuticals Company Limited

Michio Nakai

Izumu Saito

Naoki Tohdoh

Kazuo Komiya

Masashi Murata

Yumi Kanegae

The present invention provides a novel adenovirus vector for which inflammation during the in vivo administration thereof is alleviated by inhibiting the induction of expression of an adenovirus gene by a foreign promoter inserted into the adenovirus genome, and a method for producing the vector, a cell line for use in the production of the recombinant adenovirus vector, or a gene therapy method using the recombinant adenovirus vector.

Recombinant adenovirus vector having a reduced side effect

A recombinant DNA virus for transfecting an animal cell and bearing a foreign gene and a promoter capable of regulating expression of the foreign gene is completely deleted of the function of E2A gene. The recombinant DNA virus can thus stably transduce the foreign gene into various animal cells, which leads to continuous expression of the foreign gene in the animal cells. The continuous expression of the foreign gene can provide an effective treatment of hereditary disease.

Recombinant adenovirus with removed EZA gene and method of preparation

Growing community of inventors

Ibaraki, Japan

Michio Nakai